IL-17A 蛋白, Mouse (CHO)

IL-17A is a homodimeric cytokine and plays a critical role in host defense mechanisms against many bacterial and fungal pathogens as well as allergic and autoimmune responses. IL-17A induces the production of antimicrobial peptides, cytokines, chemokines, and matrix metalloproteinases^[1][2]. IL-17A Protein, Mouse (CHO) is a recombinant mouse IL-17A protein and is expressed in CHO cells. It consists of 133 amino acids (A26-A158).

白细胞介素-17A (IL-17A)，也称为 CTLA-8，属于 IL-17 细胞因子家族。IL-17A 在记忆性 Th17 细胞中表达，是记忆性 CD4⁺ T 细胞的产物。IL-17A 也由多种免疫细胞产生，包括 CD8⁺ T 细胞、γδT 细胞、自然杀伤 T (NKT) 细胞、单核细胞和中性粒细胞^[1][2][3]。
小鼠IL-17A与人氨基酸序列同一性为63.23%，与大鼠氨基酸序列同一性为87.33%。
IL-17A 在宿主针对许多细菌和真菌病原体的防御机制以及过敏和自身免疫反应中发挥着关键作用。IL-17A 诱导抗菌肽（防御素和 S100 蛋白）、细胞因子（IL-6、G-CSF 和 GM-CSF）、趋化因子（CXCL1、CXCL5、IL-8、CCL2 和 CCL7）和基质的产生金属蛋白酶（MMP1、MMP3 和 MMP13）。IL-17A 通过促进中性粒细胞炎症而对病毒感染有害。IL-17A 是同型二聚体细胞因子，与 IL-17F 具有相似的生物活性。IL-17A与IL-17RA以高亲和力结合，IL-17RA是IL-17A生物活性所必需的。在肿瘤发生过程中，IL-17A 会募集骨髓源性抑制细胞 (MDSC) 来抑制抗肿瘤免疫。IL-17A 还可通过诱导 IL-6^[1][2] 促进体内肿瘤生长。
IL-17A 可用于研究自身免疫性疾病、感染和癌症^[1][4]。

Recombinant mouse interleukin 17 (rmIL-17) (0.1 or 0.9 μg/rat/day; nasally; 6 days) shows increased infiltration of inflammatory cells into the sciatic nerve, more severe demyelination, augmented proliferation of regional lymph node cells, and increased serum levels of tumor necrosis factor-α in chronic experimental autoimmune neuritis (EAN) induced Lewis rats^[5].
rmIL-17A (625 ng/mouse; i.t.; once) dramatically synergizes TNF-alpha induced neutrophil accumulation in C57BL/6 mice^[6].

1.Full biological activity determined by its ability to induce IL-1a, IL-4 and IL-6 production by primary mouse splenocytes.
2. Measured by its ability to induce IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells. The ED₅₀ for this effect is 1.115 ng/mL, corresponding to a specific activity is 8.969×10⁵ U/mg.

Mouse

CHO

Tag Free

Q62386 (A26-A158)

16171  [NCBI]

AAIIPQSSACPNTEAKDFLQNVKVNLKVFNSLGAKVSSRRPSDYLNRSTSPWTLHRNEDPDRYPSVIWEAQCRHQRCVNAEGKLDHHMNSVLIQQEILVLKREPESCPFTFRVEKMLVGVGCTCVASIVRQAA

Approximately 15-22 kDa due to the glycosylation.

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized after extensive dialysis against PBS.

<0.2 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Chen K, et al. Interluekin-17A (IL17A). Gene. 2017 May 30;614:8-14.  [Content Brief]

  [2]. Iwakura Y, et al. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008 Dec;226:57-79.  [Content Brief]

  [3]. Cua DJ, et al. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010 Jul;10(7):479-89.  [Content Brief]

  [4]. Wright JF, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008 Aug 15;181(4):2799-805.  [Content Brief]

  [5]. Pelidou SH, et al. Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role. Exp Neurol. 2000 May;163(1):165-72.  [Content Brief]

  [6]. Liu Y, et al. IL-17A and TNF-α exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. J Immunol. 2011 Mar 1;186(5):3197-205.  [Content Brief]